Pancreatic cancer is a tough fight. Many patients receive a powerful combination of drugs called FOLFIRINOX. This treatment uses 5-fluorouracil, irinotecan, and oxaliplatin to try to stop the disease. But these drugs can be hard on the body. A new look at data from UCSF oncology clinics shows how often doctors had to step in.
Out of 514 patients studied, more than 60% required at least one dose modification. This means the doctors lowered the amount of medicine given to keep patients safe. On average, patients received a median of six chemotherapy cycles before stopping or changing the plan. The study used computer models to see how well data from electronic records could predict these changes.
The models performed differently depending on the specific drug. Some predictions were better than others. This suggests that current hospital records do not fully capture the complex reasons behind dosing decisions. The research team notes that future tools need to include patient-reported symptoms and function. They also need to be tested in many different clinics to work for everyone.